Processa pharmaceuticals announces prioritization on development of next generation chemotherapies

Hanover, md, feb. 21, 2023 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”) reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as next generation chemotherapies (ngcs). previous studies with these ngcs suggest potential improvement in the safety-efficacy profile will significantly differentiate these ngcs from their three presently widely used counterparts - capecitabine, gemcitabine, and irinotecan.
PCSA Ratings Summary
PCSA Quant Ranking